Mylan’s ‘Investor Logic’ For Acquisition Could Support Perrigo’s Rejection
This article was originally published in The Tan Sheet
Mylan targeted Perrigo as soon as it could, after acquiring Abbott Laboratories’ non-U.S. developed markets in June 2014, says CEO Heather Bresch. Her remarks at investor conference could lend support to Perrigo’s argument that Mylan’s offer does not acknowledge the value of its Omega Pharma acquisition.
You may also be interested in...
Acquiring Patheon’s Mexico plant not only adds softgel capabilities to Perrigo’s operations but also boosts its value as an acquisition target. The firm continues integrating Omega Pharma’s operations and managing its OTC private label and other businesses as Mylan presses for Perrigo shareholders to consider its bid.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.